ArticleArchives of toxicology2025
Application of in vitro pulmonary models for hazard screening of silica particles.
Article in Archives of toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Human in vitro airway models to assess point-of-contact respiratory toxicity of surfactants and derive human equivalent concentrations after single dose exposure.Toxicological sciences : an official journal of the Society of Toxicology · 2026Article
- Tools of the trade: leveraging 3DFrontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
There is an increasing need for new approach methodologies (NAMs) for safety assessment of nanomaterials (NMs) in order to keep pace with innovation. In vitro assays are useful tools during pre-market hazard screening approaches of NMs to prioritize safe(r) candidate NMs and reduce the amount of regulatory testing required. For pre-regulatory hazard screening applications, it is crucial that in vitro assays have the capacity to distinguish between NMs based on their hazard potency and have the ability to provide accurate hazard rankings. In this paper, four types of silica particles (crystalline, pyrogenic, colloidal, and silane functionalized colloidal) were subjected to twenty-four in vitro assays to obtain hazard rankings using dose-response modelling. The assays were chosen for their relevance in the mechanism of action towards pulmonary inflammation upon inhalation of silica particles. The hazard rankings of silica particles were affected by cell type (alveolar or bronchial epithelial cells, macrophages), read-out method (cell viability, release of pro-inflammatory mediators, reactive oxygen species), and exposure method (submerged, air-liquid interface), complicating the assessment of the actual human hazard. Of particular note was an often muted in vitro response to the crystalline silica used in this study (DQ12), when in vivo data ranked this material as high hazard, due to the chronic and persistent in vivo inflammatory response to crystalline silica, highlighting an important functional discord between these models. However, the potency ranking of the silica particles to induce secretion of the pro-inflammatory mediator IL-1β by THP-1 cells differentiated to M0 macrophages as well as red blood cell haemolysis corresponded more closely to the hazard ranking based on data from rat inhalation studies. These assays should be further explored as indicators for human hazard potential of silica particles and other particles following a similar mechanism of action.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.